IMR Press / EJGO / Volume 43 / Issue 1 / DOI: 10.31083/j.ejgo4301018
Open Access Review
Adjuvant treatment in endometrial cancer: when and what to choose
Show Less
1 Department of Obstetrics and Gynecology, San Gerardo Hospital, University of Milano-Bicocca, 20900 Monza (MB), Italy

Academic Editor: Enrique Hernandez

Eur. J. Gynaecol. Oncol. 2022, 43(1), 123–131;
Submitted: 31 October 2021 | Revised: 22 December 2021 | Accepted: 27 December 2021 | Published: 15 February 2022
(This article belongs to the Special Issue Endometrial Cancer)
Copyright: © 2022 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.

Endometrial cancer is the most common gynecological malignancy in developed countries. The management is primarily surgical, but adjuvant treatment may be indicated after surgery, according to the risk of recurrence. This review will focus on the prognostic risk groups presented in the 2020 ESGO/ESTRO/ESP guidelines and the ongoing trials based on new molecular markers that will help to get a more personalized cancer medicine.

Endometrial carcinoma
Adjuvant treatment
Molecular markers
Risk factors
Fig. 1.
Back to top